正常排卵妇女体外受精或卵胞浆内单精子注射治疗中控制性卵巢过度刺激期间使用Utrogestan联合「全胚冷冻」策略:100 mg与200 mg随机对照剂量探索研究
本研究为前瞻性对照研究,纳入150例接受IVF/ICSI治疗的不孕患者,比较Utrogestan 100 mg/d与研究组和200 mg/d对照组的临床特征。主要结局为早发LH峰发生率。结果显示100 mg组与200 mg组在获卵数、成熟卵母细胞数、可移植胚胎数、临床妊娠率和种植率方面无显著差异,100 mg组深度LH抑制(LH<1.2 IU/L)患者数显著少于200 mg组。结论认为100 mg Utrogestan在减少控制性卵巢过度刺激期间早发LH峰方面与200 mg同样有效。
要点
- Utrogestan 100 mg/d与200 mg/d联合hMG方案在IVF/ICSI中减少早发LH峰同样有效。
- 100 mg组深度LH抑制(LH<1.2 IU/L)患者数显著少于200 mg组。
- 两组获卵数、成熟卵母细胞数、可移植胚胎数、临床妊娠率和种植率无显著差异。
核心结论
- Utrogestan 100 mg在减少控制性卵巢过度刺激期间早发LH峰方面与200 mg同样有效。
研究设计与样本
- 前瞻性对照研究,在三级学术医疗中心开展,共纳入150例接受IVF/ICSI治疗的不孕患者。
- Utrogestan与hMG自周期第3天起同时给药,研究组Utrogestan剂量为100 mg/d,对照组为200 mg/d。
- 优势卵泡成熟时使用0.1 mg GnRH激动剂触发,两组均冷冻保存可存活胚胎以备后续移植。
主要发现
- 100 mg组深度LH抑制(LH<1.2 IU/L)患者数显著少于200 mg组。
- 100 mg组获卵数与200 mg组相似(9.87 ± 5.77 vs. 10.25 ± 5.43)。
- 两组在成熟卵母细胞数、可存活胚胎数、临床妊娠率和种植率方面均无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the clinical characteristics in a Utrogestan and hMG protocol with the use of different doses of Utrogestan in normally ovulating women undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatments. DESIGN: Prospective controlled study. SETTING: Tertiary-care academic medical center. PATIENT(S): A total of 150 infertile patients undergoing IVF/ICSI treatments. INTERVENTION(S): Utrogestan and hMG were administered simultaneously beginning on cycle day 3. The dose of Utrogestan was 100 mg/d in the study group and 200 mg/d in the control group. When the dominant follicles reached mature, 0.1 mg GnRH agonist was used for trigger. Viable embryos were cryopreserved in both protocols for later transfer. MAIN OUTCOME MEASURE(S): The primary outcome measure was the incidence of premature LH surge. Secondary outcomes included the embryo results and clinical pregnancy outcomes. RESULT(S): Consistent LH suppression was achieved during controlled ovarian hyperstimulation with Utrogestan at 100 mg, and the number of patients with profound LH suppression (LH <1.2 IU/L) in the low-dose group was significantly less than that in the high-dose group. The number of oocytes retrieved in the low-dose group was similar to that in the high-dose group (9.87 ± 5.77 vs. 10.25 ± 5.43). No significant differences were observed in the number of mature oocytes, viable embryos, clinical pregnancy rate, or implantation rate. CONCLUSION(S): Utrogestan at 100 mg is as effective as Utrogestan at 200 mg in reducing premature LH surge during controlled ovarian hyperstimulation. CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR-OOC-14005277.
引用
- Zhu X, Ye H, Fu Y, et al. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a "freeze all" strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertil Steril. 2016. PMID: 27865446. doi:10.1016/j.fertnstert.2016.10.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。